Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.65 |
| ▸ | HTR2A | P28223 | 3/20 | 0.53 |
| ▸ | HTR2C | P28335 | 3/20 | 0.53 |
| ▸ | PDE4A | P27815 | 1/20 | 0.52 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.52 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.52 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.52 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.38 |
| ▸ | TLR2 | O60603 | 6/20 | 0.38 |
| ▸ | LMNA | P02545 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | HTT | P42858 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11746236 | 0.83 | KDM4E (0.77) | KDM4ESMN1; SMN2CYP1A2HTR2AHTR2C | |
| SCHEMBL6334232 | 0.81 | KDM4E (0.44) | KDM4ESMN1; SMN2CYP1A2HTR2AHTR2C | |
| Flumequine SCHEMBL49829 | 0.79 | KDM4E (1.00) | KDM4ESMN1; SMN2CYP1A2HTR2AHTR2C | |
| SCHEMBL5796602 | 0.79 | KDM4E (0.39) | KDM4ESMN1; SMN2CYP1A2HTR2AHTR2C | |
| Flumequine SCHEMBL29465201 | 0.79 | KDM4E (1.00) | KDM4ESMN1; SMN2CYP1A2HTR2AHTR2C | |
| Flumequine SCHEMBL30767693 | 0.79 | KDM4E (1.00) | KDM4ESMN1; SMN2CYP1A2HTR2AHTR2C | |
| Flumequine SCHEMBL49830 | 0.79 | KDM4E (1.00) | KDM4ESMN1; SMN2CYP1A2HTR2AHTR2C | |
| SCHEMBL13923336 | 0.78 | KDM4E (0.77) | KDM4ESMN1; SMN2CYP1A2HTR2AHTR2C | |
| SCHEMBL11747062 | 0.78 | KDM4E (0.80) | KDM4ESMN1; SMN2CYP1A2HTR2AHTR2C | |
| SCHEMBL11742001 | 0.78 | KDM4E (0.80) | KDM4ESMN1; SMN2CYP1A2HTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6867198-B2 | Agents and methods for the treatment of proliferative diseases | ELI LILLY AND COMPANY (US) | 2005-03-15 | — | — | US | disclosed |
| US-20030229026-A1 | Agents and methods for the treatment of proliferative diseases | ELI LILLY AND COMPANY | 2003-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030229026-A1 | Agents and methods for the treatment of proliferative diseases | MKI67, CDKN1A, CDK1 | KDM4E 2625/4885SMN1; SMN2 2878/4885CYP1A2 3552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.